Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication CRESTOR is indicated: • To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults at increased risk for CV events. • As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C): ∘ in adults with hypercholesterolemia. FDA label
Also known as rosuvastatin, warfarin, coumadin ABT-335, fenofibric acid, Trilipix Rosuvastatin, coumadin, ABT-335, Rosuvastatin (AZD4522)
CRESTOR · 44 trials · 30 indications
CIMT measurements were made from ultrasound images of the common carotid artery (CCA), carotid bulb and internal carotid artery (ICA). The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. Twelve carotid artery sites were scanned at each visit and the 3 images recorded at the 3 interrogation angles were measured to determine the maximum of the CIMT for a specific segment. The annualized rate of change in the MeanMax CIMT measurements from each of the 12 sites, based on all scans performed during the study, was determined using a multi-level linear mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.
Height z-score is a dimensionless quantity derived by subtracting the population mean from the individual raw score, and then deviding the difference by the pouulation SD of the reference population. This indicates how many SDs and observation is above or below the general population mean.
Change in low density lipoprotein cholesterol (LDL C) following 6 weeks of rosuvastatin 20 mg compared to 6 weeks of placebo treatment
Change in low density lipoprotein cholesterol (LDL C) following 6 weeks of rosuvastatin 20 mg compared to 6 weeks of placebo treatment
Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a two-sided significance level of 0.025 on ITT population.
Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.025 on ITT population.
Change in PAV computed as PAV(Week 104)-PAV(baseline) where PAV is calculated as: \[sum(EEMcsa-LUMENcsa)/sum EEMcsa\]\*100 where EEMcsa is the cross-sectional area of the external elastic membrane and LUMENcsa is the cross-sectional area of the lumen, as measured by intravascular ultrasound IVUS of a coronary artery in patients with CAD.
Percent change in LDL-C = (Combination treatment value - Baseline value)/Baseline value\*100
Percent change in low-density lipoprotein cholesterol (LDL-C) = (final value - Baseline value)/Baseline value \* 100
To characterise the single dose and steady state PK of AZD0780 following oral administration of AZD0780 (PART A)
To characterise the single dose and steady state PK of AZD0780 following oral administration of AZD0780 (PART A)
To characterise the single dose and steady state PK of AZD0780 following oral administration of AZD0780 (PART A)
To characterise the single dose and steady state PK of AZD0780 following oral administration of AZD0780 (PART A)
To compare the effect of treatment with AZD0780 versus placebo on LDL-C at 12 weeks (PART B)
Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 \[LOCF\] urine protein/creatinine ratio over baseline urine protein/creatinine ratio.
Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 \[LOCF\] urine protein/creatinine ratio over baseline urine protein/creatinine ratio.
ln-transformed Cmax,ss of baseline-adjusted (primary analysis) and unadjusted (secondary analysis) total EPA, total DHA, and total EPA+DHA using a linear mixed effect model.
ln-transformed AUC0-tau of baseline-adjusted (primary analysis) and unadjusted (secondary analysis) total EPA, total DHA, and total EPA+DHA using a linear mixed effect model.
| Arm | Type | Description |
|---|---|---|
| Rosuvastatin | EXPERIMENTAL | 20 mg tablets, Daily oral dose |
| Placebo | PLACEBO_COMPARATOR | Matching placebo tablets |
| Single Arm | EXPERIMENTAL | One treatment period for all patients (\<1 year and 10 months), with the possibility to up-titrate dose to 40 mg of rosuvastatin for non-Asian patients. |
| 1 | EXPERIMENTAL | Rosuvastatin 5mg qd |
| 2 | EXPERIMENTAL | Rosuvastatin 10mg qd |
| 3 | ACTIVE_COMPARATOR | Atorvastatin 10mg qd |
| Rosuvastatin 20 mg | EXPERIMENTAL | Rosuvastatin 20 mg distributed in 2-week run-in period |
| Atorvastatin 40 mg | ACTIVE_COMPARATOR | Atorvastatin 40 mg distributed in 2-week run-in period |
| Rosuvastatin 40 mg | EXPERIMENTAL | Rosuvastatin 40 mg distributed in core 2-year study |
| Atorvastatin 80 mg | ACTIVE_COMPARATOR | Atorvastatin 80 mg distributed in core 2-year study |
| rosuva 5 | ACTIVE_COMPARATOR | rosuvastatin 5 mg |
| rosuva 10 | ACTIVE_COMPARATOR | rosuvastatin 10 mg |
| rosuva 20 | ACTIVE_COMPARATOR | rosuvastatin 20 mg |
| rosuva ol | OTHER | rosuvastatin open label |
| Rosuvastatin 10mg | EXPERIMENTAL | - |
| 4 | ACTIVE_COMPARATOR | Simvastatin |
| AZD0780 +Rosuvastatin Dose 1 (Part A) | EXPERIMENTAL | * Participants will receive Rosuvastatin Dose 1 QD for minimum 21 days (up to 28 days) * Then receive AZD0780 QD as add on for next 28 days (Part A) |
| Placebo +Rosuvastatin Dose 1 (Part A) | PLACEBO_COMPARATOR | * Participants will receive Rosuvastatin Dose 1 QD for minimum 21 days (up to 28 days) * Then receive Placebo QD as add on for next 28 days (Part A) |
| AZD0780 +Rosuvastatin Dose 2 (Part A) | EXPERIMENTAL | * Participants will receive Rosuvastatin Dose 2 QD for minimum 21 days (up to 28 days) * Then receive AZD0780 QD as add on for next for 28 days (Part A) |
| Placebo + Rosuvastatin Dose 2 (Part A) | PLACEBO_COMPARATOR | * Participants will receive Rosuvastatin Dose 2 QD for minimum 21 days (up to 28 days) * Then receive Placebo QD as add on for 28 days (Part A) |
| AZD0780 (Part B Cohort 1) | EXPERIMENTAL | • Participate will receive AZD0780 QD for 52 weeks (Part B Cohort 1) |
| Placebo (Part B Cohort 1) | PLACEBO_COMPARATOR | • Participate will receive Placebo QD for 52 weeks (Part B Cohort 1) |
| AZD0780+Rosuvastatin Dose 1 (Part B Cohort 2) | EXPERIMENTAL | * Participate receive Rosuvastatin Dose 1 for 28 days. * Then receive AZD0780 QD as add on for 12 weeks (Part B Cohort 2) |
| Placebo+Rosuvastation Dose 1 (Part B Cohort 2) | PLACEBO_COMPARATOR | * Participate receive Rosuvastatin Dose 1 for 28 days. * Then receive Placebo QD as add on for 12 weeks (Part B Cohort 2) |
| Epanova® | EXPERIMENTAL | Multiple oral doses of 2 g (2 x 1 g capsules) Epanova® QD for 10 consecutive days (Days 4 to 13) |
| Epanova® + Crestor® | EXPERIMENTAL | Epanova® multiple oral doses of 4 g (4 x 1 g capsules) QD for 13 consecutive days (Days 14 to 26) with coadministration of single 40 mg (1 x 40 mg tablet) oral dose of rosuvastatin (Crestor®) with the 11th dose of 4 g Epanova® on Day 24 |
| Vascepa® | ACTIVE_COMPARATOR | Vascepa® multiple oral doses of 2 g (2 x 1 g capsules) every 12 hours for 20 consecutive days (Days 1 to 20). |
| Simvastatin | EXPERIMENTAL | Single, oral dose of simvastatin 40 mg in first period and in second period (after wash out) fostamatinib 100 mg twice daily, then single oral dose of simvastatin 40 mg plus continued oral dosing of fostamatinib 100 mg twice daily, then continue fostamatinib 100 mg twice daily |
| Name | Type | Description |
|---|---|---|
| Rosuvastatin | DRUG | 20mg tablets, orally once daily for the duration of the 104-week treatment period |
| Placebo | DRUG | Matching placebo tablets, orally once daily for the duration of the 104-week treatment period. |
| Rosuvastatin 20mg | DRUG | Active drug 1 or 2 tablets will be taken taken orally, QD, either in the morning or in the evening |
| Atorvastatin | DRUG | Capsule/Tablet, 10mg, oral, qd, 6 weeks |
| Rosuvastatin (Crestor) | DRUG | 10mg and 20 mg |
| Ezetimibe | DRUG | 10 mg |
| Simvastatin | DRUG | 40mg and 80 mg |
| pravastatin | DRUG | 40mg |
| Positron emission tomography | PROCEDURE | - |
| CRESTOR | DRUG | - |
| aortic pulse wave velocity measurements | PROCEDURE | - |
| 10mg Rosuvastatin | DRUG | - |
| Maintenance of specific diet | BEHAVIORAL | - |
| Cholesterol lowering diet | BEHAVIORAL | - |
| Rosuvastatin Dose 1 | DRUG | Administered orally as tablets |
| Rosuvastatin dose 2 | DRUG | Administered orally as tablets |
| AZD0780 | DRUG | Administered orally as tablets |
| rosuvastatin 40 mg tablet | DRUG | Single oral dose of 40 mg (1 x 40 mg tablet) rosuvastatin (Crestor®) (Day 1). |
| Epanova™ QD (2 x 1 g capsules) | DRUG | Multiple oral doses of 2 g (2 x 1 g capsules) Epanova™ QD for 10 consecutive days (Days 4 to 13) |
| Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose | DRUG | Multiple oral doses of 4 g Epanova™ QD for 13 consecutive days with coadministration of single 40 mg oral dose of rosuvastatin (Crestor®) with the 11th dose of Epanova™ on Day 24 |
| Multiple (20) oral doses of 2 g Vascepa® every 12 hours | DRUG | Multiple oral doses of 2 g (2 x 1 g capsules) Vascepa® every 12 hours for 20 consecutive days (Days 1 to 20). |
| Fostamatinib | DRUG | 100-mg tablet |
Inclusion Criteria: * Provision of informed consent prior to any study-specific procedures * Male aged ≥45 and \<70 years or female aged ≥55 and \<70 years * Subjects with only hypertension (as defined blood pressure ≥140/90 mmHg or on antihypertensive treatment) and age as CVD risk factors and sub...
Top 16 of 30 competitors
CRESTOR is a small molecule being studied for heart failure. It is an investigational treatment evaluated in a Phase 3 clinical trial in patients with heart failure. The study compared CRESTOR to placebo in subjects with heart failure, with a total enrollment of 5,013 participants.
CRESTOR is developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. AstraZeneca is conducting clinical research to evaluate CRESTOR for the treatment of heart failure.
CRESTOR is in Phase 3 clinical development for heart failure. It is an investigational drug, meaning it has not been approved for this use and is still being studied in clinical trials. One Phase 3 trial has been completed.
CRESTOR has one completed Phase 3 clinical trial, identified as NCT00206310, titled "Crestor Versus Placebo in Subjects With Heart Failure." The trial enrolled 5,013 participants and was conducted in multiple countries including Belgium, France, Germany, Spain, the United Kingdom, and the United States.
CRESTOR is a brand name for rosuvastatin, a medication in the statin class. In the context of heart failure, it is being studied as an investigational treatment. The clinical trial NCT00206310 evaluated CRESTOR versus placebo in subjects with heart failure.